Stand F35/3

2025 Edition

VETBIOLIX

France

VETBIOLIX is a VC-backed, clinical-stage, veterinary biotech company dedicated to the development of First-in-class drug candidates for osteoarthritis (OA), periodontitis (PD) and gut motility disorders. VETBIOLIX is currently leading 2 EU-multicentric, Pilot, randomized, double-blind, dose-ranging, placebo-controlled clinical studies in canine OA (VBX-2000 – A-A3 ag.) and canine PD (VBX-1000 – Cath-K Inh.), and 2 Proof of concept clinical studies in canine / feline GMD (VBX-3000 – 5-HT4 ag.).

Scroll to Top
  • No products in the cart.